Position in NVS
as of Mar 31, 2026
· filed Apr 15, 2026
Position Value
$559,674
+$81,820 QoQ
Shares Held
3,664
+5.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
10 quarters on record
Voting authority
Sole 0%
Shared 91%
None 9%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026JOURNEY STRATEGIC WEALTH LLC holds $1,735,111,643 across 11 Drug Manufacturers - General names. NVS ranks #10 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
6,998,885 | $1,710,807,445 | |
| 2 | LLY |
ELI LILLY & Co
|
7,471 | $6,871,596 | |
| 3 | ABBV |
AbbVie Inc.
|
24,928 | $5,421,586 | |
| 4 | MRK |
Merck & Co., Inc.
|
32,079 | $3,858,779 | |
| 5 | AMGN |
Amgen Inc
|
5,915 | $2,081,188 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
11,794 | $1,643,727 | |
| 7 | PFE |
Pfizer Inc
|
57,557 | $1,616,198 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
20,837 | $1,263,760 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $559,674 | 3,664 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $477,854 | 3,466 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $433,448 | 3,380 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $401,387 | 3,317 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $368,329 | 3,304 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $281,516 | 2,893 | Shares | Sole | 2025-01-24 | |
| 2024-09-30 | $319,179 | 2,775 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $292,551 | 2,748 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $241,438 | 2,496 | Shares | Other | 2024-05-13 | |
| 2022-12-31 | $214,007 | 2,359 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||